Company / Cash & Equivalents
Arcutis Biotherapeutics, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$42.9M
FY2025
5-year range
$42.9M / $96.4M
FY2021-FY2025
Trend
-39.9%
vs FY2024
Sector context
#187 of 207
Health Care
What the data says
Among 207 Health Care companies, Arcutis Biotherapeutics, Inc. is in the bottom 10% for cash & equivalents. Cash & Equivalents has fluctuated over the past 7 years, ranging from $43M in FY2025 to $96M in FY2021.
Based on SEC 10-K filings.
$43M in FY2025 with a 5-year CAGR of -8.0%.
Declined from $88M to $43M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -7.2%
- 5-Year CAGR
- -8.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 207This company $42.9M Sector average $669.5M
▼
-93.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -8.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 39.9% year-over-year.
- Ranks #187 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.9M | -39.9% |
| FY2024 | $71.3M | -19.3% |
| FY2023 | $88.4M | +64.8% |
| FY2022 | $53.6M | -44.4% |
| FY2021 | $96.4M | +48.2% |
| FY2020 | $65.1M | +2.8% |
| FY2019 | $63.3M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026